Discussion
Over the coming months, Atyr Pharma will be working toward the launch of a global clinical trial testing its therapy candidate efzofitimod in people with moderate to severe pulmonary sarcoidosis and restrictive lung disease, which together make it difficult for the lungs to fully expand, hampering breathing. The…